Objective: The menopausal transition is associated with an increase in risk for cardiovascular disease; however, whether variability in reproductive aging relates to cardiovascular risk factors in the premenopausal period has not been studied.
T he menopausal transition is associated with an increase in risk for cardiovascular disease (CVD), 1<12 the leading cause of death in women. 13 As the number of US postmenopausal women rises, 14 proportionate increases in CVD will have enormous public health implications. Despite this, there is a paucity of research examining the relation between variability in reproductive aging and CVD risk in the premenopausal period, a time when interventions to slow menopause onset and/or lessen the clinical impact of its sequelae may be possible. Recent methodological advances in the measurement of reproductive agingVincluding the assessment of antimüllerian hormone (AMH), a biochemical marker of ovarian reserveVare now opening up new opportunities to address this gap in our knowledge.
AMH is a hormone secreted by granulosa cells of the preantral and small antral follicles of the human ovary. 15 AMH plays a key role in inhibiting the early stages of follicle growth, thereby preserving ovarian reserve by limiting initial recruitment of primordial follicles into the pool of growing follicles. 16, 17 Because AMH levels are reflective of the number of small growing follicles, which are themselves proportional to the number of primordial follicles, AMH indexes the ovarian reserve. 18, 19 Support for its use in this capacity stems from studies showing that AMH correlates with the number of primordial follicles remaining in the ovary 20 ; relates inversely to chronological age in adult women 18, 21 ; predicts ovarian response in treatment protocols using assisted reproductive technologies 22, 23 and fecundity in fertile women 24 ; and relates prospectively to the timing of menopause. 25, 26 AMH also possesses several measurement advantages, making it particularly well-suited for use in epidemiological studies. That is, AMH shows excellent within-person cycle-to-cycle reproducibility, 27, 28 is stable across the menstrual cycle, 29<31 and is not impacted by the use of oral contraceptives. 31, 32 Moreover, AMH has recently been incorporated into the revised Stages of Reproductive Aging Workshop staging system for reproductive aging, albeit for supportive (and not diagnostic) purposes. 33 In the current study, we evaluated the association between reproductive aging, indexed by AMH levels, and cardiovascular risk among 951 regularly cycling, premenopausal women. The primary study objective was to examine AMH levels in relation to overall cardiovascular risk, marked by the total number of cardiometabolic risk factors calculated as the sum (range, 0-5) of the five components of metabolic syndrome: (1) triglyceride level of 150 mg/dL or higher; (2) high-density lipoprotein [HDL] level lower than 50 mg/dL; (3) homeostasis model assessment of insulin resistance [HOMA-IR] of 2.6 or higher; (4) waist circumference of 88 cm or higher for white, African-American, and Latina women, and 80 cm or higher for Chinese women; and (5) hypertensive (vs normotensive) status. Secondarily, AMH levels were examined in relation to each of these risk factors individually. We hypothesized that having a greater ovarian reserve indexed by higher AMH levels would be related to having a healthier cardiometabolic risk factor profile.
METHODS

Participants
The current sample included participants in the Ovarian Aging (OVA) Study, an investigation of the correlates of reproductive aging. Participants were recruited through Kaiser Permanente (KP) of Northern California, a large integrated healthcare delivery system that provides medical care to approximately one third of the population of Northern California. The KP membership, compared with the population of Northern California, is generally representative in its sociodemographic and health-related characteristics, especially when the comparison is limited to those with health insurance. 34 Women were included in the OVA Study if they were between 25 and 45 years of age; had regular menses; had their uterus and both ovaries intact; self-identified as white, African-American, Latina, Chinese, or Filipina; and were able to speak/ read English, Spanish, or Cantonese. Exclusions included selfreport of major medical illnesses, use of medications affecting the menstrual cycle in the 3 months before study participation, and current pregnancy or breast-feeding.
The OVA Study protocol included an in-person medical history interview, transvaginal ultrasound, anthropometric assessment, blood draw, and self-report questionnaires. Of 1,019 total participants, 951 women were included in the current analysis. Of the 68 women who were excluded, 41 (Filipina women) were excluded owing to their small number and 27 were excluded due to missing data on a variable of primary interest. The study protocol was approved by the University of California San Francisco Committee on Human Research and the KP of Northern California Institutional Review Board. Informed written consent form was obtained from all study participants.
Measures
Antimü llerian hormone
AMH (ng/mL) was assayed using two commercially available ELISAs from Beckman Coulter (Marseille, France), both of which use a two-site sandwich immunoassay. The Immunotech assay was used for most of the sample (84%) until this assay was retired, and the second-generation assay (Gen II) was used for the remainder of the samples. Among 44 women on whom both assays were performed, regression analyses showed excellent correspondence between the assays (R 2 = 0.94), which has also been demonstrated in prior studies. 35, 36 AMH values based on the Immunotech assay were adjusted using the equation of a line, with Immunotech predicting Gen II. The Gen II assay sensitivity was 0.16 ng/mL, the intra-assay coefficient of variation was 1.4%, and the interassay coefficient of variation was 12.5%.
Cardiometabolic risk factors
Parameters of cardiometabolic health were selected to represent the individual components of metabolic syndrome (triglycerides, HDL, HOMA-IR, waist circumference, and hypertensive status). Assays for triglycerides, HDL, fasting glucose, and insulin were performed by Quest Diagnostics (San Jose, CA). Lipids were assayed using enzymatic methods (triglycerides: intraassay coefficient of variation, 1.99%-3.45%; HDL: intraassay coefficient of variation, 1.15%-2.02%). Fasting glucose was assayed by the glucose oxidase method (intraassay coefficient of variation, 1.25%-2.00%), and insulin was assayed using the Siemens Immulite (Tarrytown, NY) immunochemiluminometric assay (intraassay coefficient of variation, 3.64%-6.64%). HOMA-IR was calculated as insulin (KIU/mL) Â glucose (mg/dL)/ 405. 37 Waist circumference was derived from a standardized anthropometric assessment performed by a study nurse; two measurements (to the nearest 0.1 cm) were taken at the narrowest part of the torso and averaged. Lastly, previously diagnosed hypertension (yes/no) and use of antihypertensive medications (yes/no) were derived from an in-person medical history interview; endorsement of one or both items was used as a surrogate for elevated systolic/diastolic blood pressure, which was not assessed in the study protocol. Risk factors were coded dichotomously according to commonly used clinical cutoffs as follows: (1) triglycerides (1 = Q150 mg/dL; 0 = G150 mg/dL); (2) HDL (1 = G50 mg/dL; 0 = Q50 mg/dL); (3) HOMA-IR (1 = Q2.6; 0 = G2.6) 38 ; (4) waist circumference (1 = Q88 cm; 0 = G88 cm for white, African-American, and Latina women; 1 = Q80 cm; 0 = G80 cm for Chinese women); and (5) hypertensive status (1 = hypertension diagnosis/use of antihypertensive medication; 0 = no hypertension diagnosis/use of antihypertensive medication). In addition, a summary score was computed reflecting the total number of cardiometabolic risk factors possessed by each participant (range, 0-5).
Analytical plan
First, to address the primary study objective, negative binomial regression analyses were performed to model the relation between AMH levels and number of cardiometabolic risk factors. AMH levels (categories: low, mid, and high) were derived by dividing the AMH distribution into tertiles. The number of cardiometabolic risk factors was derived by taking the simple sum (possible range, 0-5) of the five components of metabolic syndrome coded as follows: (1) triglycerides (1 = Q150 mg/dL; 0 = G150 mg/dL); (2) HDL (1 = G50 mg/dL; 0 = Q50 mg/dL); (3) HOMA-IR (1 = Q2.6; 0 = G2.6); (4) waist circumference (1 = Q88 cm; 0 = G88 cm for white, African-American, and Latina women; 1 = Q80 cm; 0 = G80 cm for Chinese women); and (5) hypertensive status (1 = hypertension diagnosis/use of antihypertensive medication; 0 = no hypertension diagnosis/use of antihypertensive medication). Results for models adjusted for age and adjusted for covariates (age, cigarette smoking, race/ethnicity, menarcheal age, past use of hormonal contraception, and parity) are reported. Cigarette smoking was coded: 1 = current/past smoking, 0 = never smoked; race/ethnicity was dummy-coded using white as the reference group; past use of hormonal contraception was coded: 1 = past use, 0 = no use; and parity was coded: 1 = one or more live births, 0 = no live births. Next, in secondary analyses, logistic regression analyses were performed to examine the relation between AMH levels and individual cardiometabolic risk factors using the same dichotomous coding as described above. Results for models adjusted for age and adjusted for covariates (age, cigarette smoking, race/ ethnicity, menarcheal age, past use of hormonal contraception, and parity) are reported. Lastly, to characterize the role of obesity in explaining associations between AMH levels and cardiometabolic risk, all analyses were repeated additionally including body mass index (BMI) as a covariate. Analyses were performed using SAS statistical software version 9.3.
RESULTS
Sample characteristics
The mean (SD) age of the sample (N = 951) was 35.2 (5.5) years, and the racial/ethnic composition included 29.3% white, 24.9% African-American, 23.4% Latina, and 22.4% Chinese women. The AMH distribution was divided into tertiles representing low (n = 317), mid (n = 317), and high (n = 317) AMH levels. In the low AMH tertile, the mean (SD) [ 42-19.28 ]. Descriptive information for the full sample and for women in each AMH tertile is reported in Table 1 . As expected, age varied significantly across AMH tertiles, with the mean age progressively decreasing across low, mid, and high AMH levels (P G 0.001). With respect to race/ethnicity, there was a significant difference in the proportion of white women in the low (22.7%) versus high (36.0%) AMH tertiles (P G 0.05). There were also significant differences in the proportion of Latina women in the low (29.3%) versus mid (21.8%) AMH tertiles and in the low (29.3%) versus high (19.2%) AMH tertiles (Ps G 0.05). With respect to cardiometabolic risk factors, the proportion of women with low HDL (G50 mg/dL), high glucose (Q100 mg/dL), high waist circumference (race-specific cutoff or higher), and hypertension (yes/no) was significantly higher in the low versus high AMH tertile (Ps G 0.05). The proportion of women with low HDL (G50 mg/dL), high waist circumference (race-specific cutoff or higher), and hypertension (yes/no) was also significantly higher in the mid versus high AMH tertile (Ps G 0.05). Lastly, the proportion of obese women (BMI Q30 kg/m 2 ) varied significantly between all AMH tertiles (Ps G 0.05), with the proportion of obese women decreasing across low, mid, and high AMH levels.
Association of AMH and overall number of cardiometabolic risk factors
Negative binomial regression analyses were performed to model the number of cardiometabolic risk factors (possible range, 0-5) as predicted by AMH levels (categories: low, mid, and high). Results of age-adjusted (model 1) and covariateadjusted (model 2) models are reported in Table 2 . Results showed that, independently of age, the number of cardiometabolic risk factors was 52.1% higher (95% CI, 1.215-1.905) among women with low versus high AMH levels and 46.0% higher (95% CI, 1.181-1.806) among women with mid versus high AMH levels. In addition, results of analyses examining the predicted number of cardiometabolic risk factors across AMH levels at five prespecified ages (ie, 25, 30, 35, 40 , and 45 y) are described in the following. Estimated at age 25 years, the predicted number of cardiometabolic risk factors was 0.95, 0.91, and 0.62 for low, mid, and high AMH levels, respectively. In parallel, values were 1.00, 0.96, and 0.66 (at age 30 y); 1.06, 1.02, and 0.70 (at age 35 y); 1.13, 1.08, and 0.74 (at age 40 y); and 1.19, 1.15, and 0.78 (at age 45 y) for low, mid, and high AMH levels, respectively. Figure 1 depicts these results, showing that the number of cardiometabolic risk factors was related positively to age and that, at every age, a greater number of cardiometabolic risk factors was predicted by low AMH levels relative to high AMH levels, as well as by mid AMH levels relative to high AMH levels. When analyses were repeated after additionally controlling for covariates (cigarette smoking, race/ethnicity, menarcheal age, past use of hormonal contraception, and parity; model 2), a similar pattern of results was found. That is, the number of cardiometabolic risk factors was 27.2% higher (95% CI, 1.037-1.561) among women with low versus high AMH levels and 31.1% higher (95% CI, 1.079-1.592) among women with mid versus high AMH levels.
Association of AMH and individual cardiometabolic risk factors
Logistic regression analyses were performed to examine AMH levels (comparing low and mid levels with high levels) in relation to individual cardiometabolic risk factors. Results of age-adjusted (model 1) and covariate-adjusted (model 2) models are reported in Table 3 . In age-adjusted models, AMH levels were related significantly to HDL, waist circumference, and hypertensive status (but not to triglycerides or HOMA-IR). Specifically, with respect to HDL, low versus high AMH levels were associated with an 81% (odds ratio [OR], 1.814; 95% CI, 1.211-2.718) increased odds of having HDL G50 mg/dL versus Q50 mg/dL; and mid versus high AMH levels were associated with a 57% (OR, 1.568; 95% CI, 1.083-2.269) increased odds of having HDL G50 mg/dL versus Q50 mg/dL. With respect to waist circumference, low versus high AMH levels were associated with a 101% (OR, 2.012; 95% CI, 1.380-2.934) increased odds of having a waist circumference equal to or higher than the racespecific cutoff versus having a waist circumference lower than the race-specific cutoff; and mid versus high AMH levels were associated with an 88% (OR, 1.881; 95% CI, 1.333-2.654) increased odds of having a waist circumference equal to or higher than the race-specific cutoff versus having a waist circumference lower than the race-specific cutoff. With respect to hypertensive status, low versus high AMH levels were associated with a 137% (OR, 2.373; 95% CI, 1.095-5.143) increased odds of being hypertensive versus being normotensive; and mid versus high AMH levels were associated with a 105% (OR, 2.052; 95% CI, 0.976-4.314) increased odds of being hypertensive versus being normotensive. In models additionally adjusted for covariates (cigarette smoking, race/ ethnicity, menarcheal age, past use of hormonal contraception, and parity), associations between AMH levels and HDL, waist circumference, and hypertensive status outcomes persisted, albeit at the level of a statistical trend for HDL and hypertensive status (Ps G 0.10).
Role of BMI in explaining associations between AMH and cardiometabolic risk factors
Follow-up analyses were performed to characterize the potential role of BMI in explaining associations between AMH levels and the overall number of cardiometabolic risk factors, as well as AMH levels and individual cardiometabolic risk factors. First, negative binomial regression analyses were again performed to model the number of cardiometabolic risk factors as predicted by AMH levels (categories: low, mid, and high), but this time excluding waist circumference from the summary score (possible range, 0-4). Results showed that, independently of age, the number of cardiometabolic risk factors was 48.1% higher (95% CI, 1.126-1.948) among women with low versus high AMH levels and 41.8% higher (95% CI, 1.096-1.835) among women with mid versus high AMH levels. In models additionally adjusted for covariates (cigarette smoking, race/ethnicity, menarcheal age, past use of hormonal contraception, and parity), associations attenuated partially, showing that the number of cardiometabolic risk factors was 24.5% higher (95% CI, 0.960-1.615) among women with low versus high AMH levels and 28.0% higher (95% CI, 1.003-1.633) among women with mid versus high AMH levels. Finally, in models additionally adjusted for BMI, associations between AMH levels and the overall number of cardiometabolic risk factors attenuated completely (Ps 9 0.10).
Next, logistic regression analyses were again performed to examine AMH levels in relation to individual cardiometabolic risk factors (excluding waist circumference). In models additionally adjusted for BMI, all associations between AMH levels and cardiometabolic risk factor outcomes, including triglycerides (low vs high AMH levels: OR, 0.734; 95% CI, 0.374-1.438; mid vs high AMH levels: OR, 0.671; 95% CI, 0.354-1.272), HDL (low vs high AMH levels: OR, 1.095; 95% CI, 0.690-1.735; mid vs high AMH levels: OR, 1.090; 95% CI, 0.716-1.658), HOMA-IR (low vs high AMH levels: OR, 0.610; 95% CI, 0.316-1.175; mid vs high AMH levels: OR, 0.838; 95% CI, 0.461-1.522), and hypertensive status (low vs high AMH levels: OR, 1.503; 95% CI, 0.672-3.361; mid vs high AMH levels: OR, 1.346; 95% CI, 0.613-2.954) were nonsignificant.
DISCUSSION
Based on previous studies showing that the menopausal transition is associated with an increase in risk for CVD, 1<12 we sought to determine whether variability in reproductive Covariates included age, cigarette smoking, race/ethnicity (reference group: white), menarcheal age, past use of hormonal contraception, and parity. b P G 0.10, c P G 0.05, d P G 0.01, e PG0.001, f Waist circumference cutoffs were 88 cm or higher for white, African-American, and Latina women, and 80 cm or higher for Chinese women. aging may similarly relate to cardiometabolic risk factors in the premenopausal period, an optimal time to prevent or delay potential reproductive agingYrelated sequelae. In the current sample of 951 healthy, regularly cycling women, AMH, a biochemical marker of ovarian reserve, was examined in relation to a summary score (range, 0-5) reflecting the total number of cardiometabolic risk factors present in each woman. In age-adjusted analyses, results showed that low and mid levels of AMH (compared with high) were associated with a 52.1% and 46.0% increase, respectively, in the number of cardiometabolic risk factors. In analyses additionally adjusted for cigarette smoking, race/ethnicity, menarcheal age, past use of hormonal contraception, and parity, associations remained statistically significant, showing that low and mid levels of AMH (compared with high) were associated with a 27.2% and 31.1% increase, respectively, in the number of cardiometabolic risk factors. Taken together, results suggest that, independently of confounding factors, having a greater ovarian reserve, marked by high AMH, was associated with having a healthier cardiometabolic risk factor profile.
In secondary analyses, AMH was also examined in relation to individual cardiometabolic risk factors, coded dichotomously according to common clinical cutoffs. In age-adjusted analyses, results showed that low and mid levels of AMH (compared with high) were associated with an increase in risk with respect to HDL, waist circumference, and hypertensive status. However, when models were additionally adjusted for cigarette smoking, race/ethnicity, menarcheal age, past use of hormonal contraception, and parity, associations with HDL and hypertensive status attenuated to the level of a statistical trend. Moreover, when all analyses were repeated with additional adjustment for BMI, associations between AMH and the total number of cardiometabolic risk factors, as well as associations between AMH and HDL/hypertensive status, fully attenuated. This pattern of resultsVin which the effects of AMH on cardiometabolic outcomes fully attenuated when BMI was covariedVsuggests that obesity may play a mechanistic role in explaining links between reproductive aging and cardiometabolic risk. Although the potential meditational role of BMI could not be directly tested in this cross-sectional data set, interestingly, evidence drawn from the menopause literature is consistent with this idea. That is, the menopausal transition has been associated with an increase in weight gain, 39 which has been thought to at least partially explain subsequent decrements in cardiometabolic risk factor profiles observed postmenopausally. 40<42 The current finding that low and mid levels of AMH (compared with high) are related to having a greater waist circumference is consistent with several previous studies showing that AMH is lower among obese women, 43<45 although not all studies have found an association between AMH and BMI. 46<48 Also, the current finding that high AMH is associated with having fewer cardiometabolic risk factors, which were selected to represent the components of metabolic syndrome, is consistent with one recent study in which AMH and HOMA-IR were shown to be inversely related, 47 although AMH and HOMA-IR were unrelated in the current study. Otherwise, because the current study is the first (to our knowledge) to systematically examine AMH in relation to conventional cardiometabolic risk factors in a large and ethnically diverse sample of healthy, regularly cycling women, its comparison with existing literature is limited. Other previous studies examining CVD in premenopausal women suggest collectively that disruptions in ovarian function are related to an increase in cardiovascular risk; however, such disruptions have been marked by indicators such as anovulation, lower estradiol, and menstrual cycle irregularity, and have not included assessments of ovarian reserve in particular. 49<55 In the current study, the proportion of white women was significantly lower in the low (23%) versus high (36%) AMH tertiles, and the proportion of Latina women was significantly greater in the low (29%) versus mid (22%) and high (19%) AMH tertiles, suggesting that there may be a relation between race/ethnicity and AMH. Although most previous studies have included samples composed of predominately white women, one study comparing AMH declines across race/ ethnic groups reported that the average decline in AMH was greater among African-American and Latina women than among white women. 48 More generally, evidence also suggests that racial/ethnic differences are present across a variety of reproductive health outcomes, including pubertal timing, outcomes of assisted reproductive technologies, and age at menopause (for review, see Butts and Seifer 56 ). In addition, consistent with a large literature documenting racial/ethnic disparities in CVD risk, 57, 58 the current study showed strong associations between race/ethnicity and cardiometabolic risk, with African-American and Latina (compared with white) women showing twofold to ninefold increases in the odds of having poorer cardiometabolic outcomes for HDL, waist circumference, and hypertensive status (results not shown). Such strong associations between race/ethnicity and the cardiometabolic outcomes likely account for the partial attenuation in the effects of AMH on HDL and hypertensive status when race/ethnicity was statistically controlled.
The current study had several weaknesses, most notably the use of a cross-sectional study design, limiting conclusions regarding the direction of association between AMH and cardiometabolic risk factor profiles. Although we conceptualized that accelerated reproductive aging, indexed by AMH, may be a risk factor for the promotion of cardiovascular risk in the premenopausal period, it is possible that cardiometabolic risk factors may also influence ovarian reserve and/or processes related to the regulation of folliculogenesis. In fact, it has been suggested in a previous study that CVD may play a causal role in the onset of earlier menopause rather than the reverse. 59 Other weaknesses of the current study included the use of having received a previous hypertension diagnosis and/or the use of antihypertensive medications as a surrogate for measured blood pressure and the absence of more definitive preclinical markers of atherosclerotic disease, such as endothelial dysfunction or carotid artery intima-media thickness. The primary strengths of the current study were its novel emphasis on examining reproductive aging in relation to cardiovascular risk in the premenopausal period among healthy, regularly cycling women, as well as its relatively large size and representation of women of racial/ethnic minorities.
CONCLUSIONS
Results of the current study provide preliminary support for the hypothesis that greater reproductive aging may relate to an increase in cardiometabolic risk in the premenopausal period, as evidenced by cross-sectional associations between having a greater ovarian reserve, marked by high AMH, and having fewer cardiometabolic risk factors. Improved understanding of links between ovarian function and cardiovascular risk may aid in identifying risk factors for atherosclerotic disease development premenopausally that are associated with variability in CVD postmenopausally. The examination of such associations in the premenopausal period may point to earlier opportunities for intervention among women at greatest risk for CVD by virtue of having an accelerated trajectory of ovarian follicle loss and, therefore, anticipated earlier entry into menopause. To flesh out these potential implications, future research should use longitudinal study designs to evaluate whether declines in ovarian reserve over time are related to cardiometabolic risk, whether associations may be bidirectional, what particular mechanisms (such as obesity) may drive such links, as well as whether such processes may operate similarly across women of different racial/ethnic backgrounds who appear to vary in terms of risk both across cardiovascular and reproductive outcomes.
